Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Automatic Data Processing

Costco

Coterra Energy

Deere & Company

Dick's Sporting Goods

Intuit

Lennar

Mastercard

Microchip Technology

M&T Bank

UnitedHealth Group

Visa

Vanguard Dividend Appreciation ETF

This monthly series of articles focuses on DGI stocks that are likely to provide a high rate of dividend growth rather than a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. A balanced portfolio should have a mix of high-dividend growth stocks and high-yield dividend stocks, depending on the life stage. If you are in the accumulation phase and are several years away from retirement, high-growth dividend stocks would be more appropriate for long-term growth.

Our Top 10 Picks For Dividend Growth Stocks - July 2023

Zoetis Inc., a leading veterinary health company, is expected to continue delivering strong earnings growth due to its dominant market position and increasing demand for pet and livestock healthcare. Despite a low dividend yield of 0.9%, Zoetis' impressive net income growth and steady margin expansion make it an attractive investment for long-term gains.

Zoetis: My Dog Approves Of This Dividend Compounder

Zoetis and Mastercard don't offer high yields, but both aggressively raised their payouts in recent years. Both companies have modest payout ratios, suggesting more hikes could be on the way.

2 Dividend Stocks That Doubled Their Payouts in 5 Years

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) today announced the addition of Ester Banque as Executive Vice President and President, U.S. Operations, for the company, effective July 10, 2023. Ms. Banque is an accomplished global senior executive with over 30 years of experience in health sciences with top tier pharmaceutical companies. Ester will be a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck. “We are excited to welcome Ester Banque to l.

Zoetis Announces Appointment of Ester Banque as President of U.S. Operations for World Leader in Animal Health

DÜSSELDORF, GERMANY / ACCESSWIRE / July 6, 2023 / Numaferm, a Germany-based biotech company, specialized in the production of pepteins, and Zoetis, the global leading animal health company, have signed a licensing agreement for the development and production of defined veterinary therapeutics. Financial details of the deal were not disclosed.

Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides

The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Zoetis (ZTS) Could Rally 27.94%: Here's is How to Trade

Allegion

Cigna

Dollar General

Domino's Pizza

Kroger

MSCI

Charles Schwab

Sirius XM Holdings Inc

SS&C Technologies Hlds

Skyworks Solutions

Tractor Supply

W. R. Berkley

The watchlist from June posted a gain of 8.91% last month, outperforming the SPDR S&P 500 Trust ETF by 2.43% and Vanguard's Dividend Appreciation ETF by 2.41%. The top 15 dividend growth stocks for July offer an average dividend yield of 1.66% and appear about 34% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is beating VIG by 4.20% and SPY by 3.81%.

My Top 15 High Growth Dividend Stocks For July 2023

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 8, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentatio.

Zoetis to Host Webcast and Conference Call on Second Quarter 2023 Financial Results

After reaching an important support level, Zoetis (ZTS) could be a good stock pick from a technical perspective. ZTS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

Zoetis (ZTS) Just Reclaimed the 20-Day Moving Average

Zoetis Inc. ( ZTS , Financial) is a leading animal health company with a diversified product portfolio of medicines and vaccines that aim to treat and protect livestock and companion animals.

There Are Plenty of Reasons to Like Zoetis

Zoetis, a global leader in the animal health industry, has beaten the S&P 500 over the last five years and offers diverse growth opportunities. The company has a strong international presence, a commitment to innovation, and a focus on key growth areas such as dermatology, parasiticides, pain, diagnostics, and emerging markets. Despite a high valuation and significant debt, Zoetis is a high-quality business that could reward patient, long-term investors.

Zoetis: A Purrfect Addition To Your Portfolio

Zoetis has more than doubled the S&P 500's return over the past decade. The animal health company's return on invested capital has risen to over 18%.

History Suggests This S&P 500 Dividend Stock Is Perfect to Buy and Hold Forever

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--Zoetis today published its 2022 Sustainability Report “Together We Are Making a Difference for a Better World”, describing the company's progress toward achieving its Driven to Care long-term sustainability aspirations and continued disclosure on environmental, social and governance (ESG) topics. The report highlights the company's journey to advance sustainability in Animal Health for a better future through specific actions that support Communities, Animals.

Zoetis Releases 2022 Sustainability Report to Share Progress in Building a Better Future for People, Animals and the Planet

MarketAxess Holdings

I present my top 15 high-growth dividend stocks to consider during the month of June. The watchlist underperformed VIG in May, but continues to outpace the ETF year-to-date and since inception. Five new stocks have been added to the watchlist for June: Intuit, Mastercard, Microchip Technology Inc., Sirius XM Holdings, and Skyworks Solutions.

My Top 15 High Growth Dividend Stocks For June 2023

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2023 Jaws and Paws Conference on Wednesday, May 31, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 3:35 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A repla.

Zoetis to Participate in the Stifel 2023 Jaws and Paws Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) is hosting an investor day at 9:00 a.m. ET today at the New York Stock Exchange, where the company will dive into its compelling growth ambitions, its innovative and robust R&D pipeline and its financial roadmap to continue delivering shareholder value, as it Shapes Animal Health for the Next Decade. During today's presentations, Chief Executive Officer Kristin Peck, Chief Financial Officer Wetteny Joseph, President of Research &.

Zoetis Holds Investor Day and Presents Strategy to Shape Animal Health for the Next Decade

Zoetis NYSE: ZTS shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company's first quarter 2023 announcements. Even after outperforming other peers in the sector, such as Bausch Health Companies NYSE: BHC and Elanco Animal Health NYSE: ELAN by as much as 32% and 75%, respectively, analyst ratings still suggest that Zoetis stock has a double-digit upside potential ceiling from today's prices.

Zoetis Declares New Dividend, Hinting At Undervaluation

WASHINGTON--(BUSINESS WIRE)--JAB Holding Company (“JAB”) today announced that its pet insurance platform has acquired a majority interest in Pumpkin Insurance Services Inc. (“Pumpkin”), a best-in-class preventive care and pet insurance provider, expanding its global leadership in the under-penetrated, fast-growing pet insurance industry. Zoetis (NYSE:ZTS), the world's largest animal health company, will maintain a significant minority stake in Pumpkin and continue its commercial partnership wit.

JAB's Pet Insurance Platform Acquires Pumpkin, Expanding its Global Leadership in the Fast-Growing Pet Insurance Industry

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.375 per share for the third quarter of 2023. The dividend will be paid on Friday, September 1, 2023, to all holders of record of the Company's common stock as of the close of business on Friday, July 21, 2023. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After inno.

Zoetis Declares Third Quarter 2023 Dividend

The article discusses Zoetis, a low-yielding dividend stock with high dividend growth potential. Zoetis is the world's leading producer of medicine and vaccinations for pets and livestock, with a global footprint of over 100 markets and more than 70 years of experience.

Zoetis' Dividend Growth: Small Yield, Big Returns

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs. Librela is the first and only once-monthly, anti-NGF monoclonal antibody treatment for canine OA pain and is approved as safe and effective in providing long-term control of OA pain symptoms in dogs, which can improve their mobility and overall quality of life.

Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs

Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.

Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

Zoetis Inc. (NYSE:ZTS ) Q1 2023 Financial Results Conference Call May 4, 2023 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Jon Block - Stifel Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Nathan Rich - Goldman Sachs Louise Chen - Cantor David Westenberg - Piper Sandler Balaji Prasad - Barclays Brandon Vazquez - William Blair Operator Welcome to the First Quarter 2023 Financial Results Conference Call and a Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.

Zoetis Inc. (ZTS) Q1 2023 Financial Results Conference Call Transcript

Zoetis (ZTS) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.32 per share a year ago.

Zoetis (ZTS) Q1 Earnings Top Estimates

Animal health behemoth Zoetis reported a mixed first quarter but kept its full-year outlook. Still, ZTS stock tumbled early Thursday.

News for Zoetis Stock (ZTS)